Bio-Techne posts Q4 FY2026 results as Merck KGaA acquisition proceeds

Bio-Techne Corporation reported financial results for the fourth quarter and full fiscal year ended June 30, 2026 on August 12, 2026.

The most significant corporate development is the pending acquisition. The company had earlier disclosed on June 25, 2026 that it agreed to be bought by Merck KGaA, Darmstadt, Germany, for $73 per share in cash, valuing the deal at roughly $11.3 billion in total enterprise value.¹ CEO Kim Kelderman said the company continues to make progress toward completing the acquisition by Merck KGaA, Darmstadt, Germany, and looks forward to the opportunities the transaction is expected to create for customers and employees.¹ Because of the pending deal, Bio-Techne is no longer holding investor conference calls for quarterly results.¹

On financial performance, fourth quarter organic revenue grew 3% (1% on a reported basis) to $321.2 million, while full-year organic and reported revenue held flat at $1.2 billion.¹ GAAP earnings per share rose to $0.35 from a loss of $0.11 a year earlier, while adjusted EPS slipped slightly to $0.52 from $0.53.¹ For the full year, GAAP EPS climbed to $1.16 from $0.46, and adjusted EPS edged up to $1.93 from $1.92.¹

By segment, Protein Sciences posted fourth quarter net sales of $231.2 million, up 2% from $226.5 million a year earlier.¹ Diagnostics and Spatial Biology segment sales were roughly flat at $90.1 million versus $89.7 million in the prior year period.¹

The release did not disclose new clinical, regulatory, or pipeline milestones; it focused on financial results and confirmation of deal progress. The company pointed investors to risk factors in its most recent Form 10-K for additional detail on forward-looking uncertainties.¹